Phase Holographic Imaging (PHI) has two option programs, both with a final subscription date of October 24, 2017. The programs, directed to board members and advisors of the Company, were implemented as the Company was listed at AktieTorget. The options are market valued according to Black & Scholes. After recalculation with reference to equity issues, option program 2012 qualifies for subscription of 43 872 shares at 16.50 SEK per share (originally 40 000 shares at 18.12 SEK) per share and option program 2013 for subscription of 209 000 shares at 12.80 SEK per share (originally 190 000 shares at 14.00 SEK per share).
Advisor Ron Lowy has now requested to exercise his entire option holdings. Hereby Lowy subscribes for 10 766 shares in option program 2012 och 44 000 shares in option program 2013, in total 54 766 shares. Lowy finances his subscription and associated taxes by divesting some of his current holdings. Through Lowy’s subscriptions, the equity of PHI will increase by 740 839 SEK.
Previously, Klas Cramborn (chairman of the board), Jan Richardsson (board member) and a former board member have exercised their entire option holdings.
For additional information, please contact:
Peter Egelberg, CEO
Tel: +46 703 19 42 74
This information is information that Phase Holographic Imaging is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at July 14, 2017.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.